Published on
16:33 GMT
FDA approves twice-yearly injection for HIV prevention
FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect Efficacy With 99.9% of Participants Remaining HIV Negative Gilead Launches Broad Access Strategy to Ensure Coverage for Both Insured …
Source:
Consumer Affairs
-
Pending
